Compare Incyte Corporation (INCY) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard International High Dividend Yield ETF — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Vanguard International High Dividend Yield ETF trades at $101.33. Which is the better fit depends on your goals.
| INCY | VYMI | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $118.52 | $101.60 |
52-Week Low | $67.38 | $79.95 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VYMI trades at $100.23, down 0.65% on the day, with a bullish technical signal driven by moving averages and strong trend momentum (ADX 6-day at 60.71). The ETF offers a forward dividend of $1.26 payable June 23, 2026. Recent news highlights its role in diversifying away from U.S. tech, with Vanguard research suggesting international stocks may outperform over the next decade.
Outlook remains positive given its low 0.07% expense ratio, high dividend yield, and diversification benefits. Risks include currency fluctuations and global economic volatility. Analyst sentiment is favorable, emphasizing sustainable dividends and attractive valuations relative to U.S. markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
